Home › Trial NCT03360721
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
- Trial IDNCT03360721
- StatusTerminated
- PhasePhase 2
- Study typeInterventional
- SponsorM.D. Anderson Cancer Center
- Enrollment7
- Start date2018-03-06
- ConditionsCastration-Resistant Prostate Carcinoma · Prostate Adenocarcinoma Without Neuroendocrine Differentiation · Stage IV Prostate Cancer AJCC v8 · Stage IVA Prostate Cancer AJCC v8 · Stage IVB Prostate Cancer AJCC v8
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.